Compare Ralph Lauren Corp (RL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Ralph Lauren (RL) trades at $361.14, down 2.04% on the day, amid a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $7.08 billion and $743 million in 2025, respectively, while profitability metrics like a 70.27% gross margin and 37.54% ROE highlight operational strength. Analyst sentiment remains bullish with a consensus price target of $456.67, though technical indicators show near-term resistance at $363.

The outlook for RL is positive based on fundamental growth and analyst support, but investors face risks from market volatility and execution challenges. The stock's current valuation at a P/E of 23.15 appears reasonable given earnings momentum, yet competitive pressures and macroeconomic factors could limit upside. Institutional confidence is high, with 66.67% of analysts rating it a buy, suggesting potential for appreciation if the company maintains its earnings trajectory.

Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.

The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.